Semax 10mg Research Peptide

For Research Purposes Only. Not approved for human consumption.

Semax Research Peptide 10mg

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) originally developed in Russia based on the adrenocorticotropic hormone (ACTH) fragment 4-10. Unlike ACTH, Semax lacks hormonal activity but retains potent neuroprotective and cognitive-enhancing properties in research models. It has been extensively studied for effects on brain-derived neurotrophic factor (BDNF), serotonin metabolism, and cerebral blood flow. Semax does not bind to classic monoamine receptors, instead working through gene expression changes and neurotrophic factor regulation.

Research Applications

• Neuroprotection and cognitive function research
• BDNF (brain-derived neurotrophic factor) pathway studies
• Cerebral blood flow and stroke recovery models
• Serotonin metabolism and antidepressant mechanism research
• Gene expression modulation in neural tissue

Quality Specifications

• Purity: ≥98% (HPLC verified)
• Compound: Semax
• Molecular Weight: 813.9 Da
• Form: Lyophilized powder
• Storage: -20°C, protect from light
• COA: Batch-specific, ISO-accredited laboratory

Frequently Asked Questions

Q: How does Semax work in research models?
A: Increases BDNF expression, modulates serotonin turnover, enhances cerebral blood flow, and alters expression of genes involved in immune regulation and neuroprotection. Does not bind monoamine receptors directly.

Q: What is BDNF and why does it matter?
A: Brain-Derived Neurotrophic Factor is a neurotrophin essential for neuronal survival, synaptic plasticity, and long-term memory formation. Semax research shows significant BDNF upregulation.

Q: How does Semax differ from ACTH?
A: Semax is derived from ACTH 4-10 but lacks the corticotropic activity. It retains neuroprotective properties without stimulating adrenal steroidogenesis.